Cottonwood’s portfolio company Exagen (investment in 2011) announces closing of Initial Public Offering. Current enterprise value of Exagen Inc is $ 305 million (a growth of 2,300% in 8.5 years). Exagen Inc. (Nasdaq: XGN) is an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.
Cowen and Company, LLC, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. acted as joint book-running managers for the offering.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on September 18, 2019. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.
The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering can be obtained from: Cowen and Company, LLC c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806, or by emailing PostSaleManualRequests@broadridge.com; from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, NY 10022, or by emailing firstname.lastname@example.org; or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by emailing email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.
Kamal Adawi Exagen Inc. 760.477.5514 KAdawi@Exagen.com Mike Cavanaugh Westwicke Partners 646.677.1838 Mike.Cavanaugh@westwicke.com